Kidnapped: Colon cancer seizes hapless nerve growth protein

December 13, 2005

Cancer works its malignant will by standing cell life on its head. No form of cancer is better at flipping normal cell mechanisms for growth and movement into sinister contraptions for evasion and invasion than aggressive colorectal tumors. Kidnapping is a particular talent, especially along the cancer's invasive edges. That's where Avri Ben-Ze'ev and colleagues at the Weizmann Institute of Science in Israel and elsewhere found an unlikely hostage to colorectal cancer in L1, a protein more commonly produced by growing nerve cells. Their findings were presented Tuesday at the 45th Annual Meeting of the American Society for Cell Biology in San Francisco.

Ben-Ze'ev and Nancy Gavert, a surgeon and current Ph.D. student--were led to the kidnapped nerve cell protein, L1, by their long-term interest in beta-catenin, a cadherin-binding protein, known to also activate genes in various types of cancer. In previous studies, the Ben-Ze'ev lab identified several beta-catenin target genes that are involved in development of malignant melanoma and colon cancer. The co-option of L1, though, was a surprise.

Analyzing patient samples of human colorectal cancer, the Ben-Ze'ev lab (in collaboration with Thomas Brabletz of the University of Erlangen in Germany) discovered L1 in large quantities exclusively in cancer cells at the aggressive and invasive front of tumors. In an additional surprise finding, the scientists found concentrations of nerve cell bundles, containing L1, located next to clusters of colon cancer cells that contain L1 on their surface. Localized on the cell membrane, L1 can serve both as a lock and a key in adhesion between cells: as a lock, it binds to L1 receptor molecules on the surface of like cells; as a key, it binds to different surface receptors of other cell types.

"That's what makes L1 so dangerous in tumors," says Ben-Ze'ev. "L1's special abilities in helping nerve cells wire up through intercellular space are hijacked by aggressive tumors to sharpen their invasive edge. The L1 protein makes them better at moving around and penetrating the body's connective tissues, as well as more resistant to adverse conditions during growth and metastasis. The discovery of L1's unwitting role in tumor cell motility and invasion may have important implications for diagnosing colon cancer and for designing new therapies," reports Ben-Ze'ev.
-end-


American Society for Cell Biology

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.